Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Denmark / NCT07807228
Recruiting Observational

Changes in Skin Myco- and Microbiome After Lebrikizumab Treatment

NCT07807228 · tracked via the Priya Life Science Denmark tracker
Sponsor
University Hospital Bispebjerg and Frederiksberg
Phase
Observational
Started
2025-06-05
Last updated
2026-09-08

Condition(s) studied

Atopic Dermatitis

Study summary

The goal of this observational study is to characterize the skin myco- and microbiome of patients with atopic dermatitis before and after initiation of treatment with lebrikizumab. The main questions it aims to answer are:

Does the skin mycobiome change with treatment? Does the skin microbiome change with treatment? Does the abundance of Staphylococcus species change with treatment?

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adults ≥18 years diagnosed with atopic dermatitis and initiating treatment with lebrikizumab Exclusion Criteria: * Previous treatment with lebrikizumab * Current treatment with other biologics or JAK-inhibitors * Hypersensitivity to lebrikizumab or any of its constituents * Pregnancy or breastfeeding * Active helminth infection

Primary outcome measure(s)

  • Changes in skin microbiome (taxinomic unit) — 16 weeks
    Collection of skin swabs at baseline, week 4 and week 16. Analyzing of skin swabs using 16S rRNA gene sequencing, TUF gene sequencing, 18S rRNA gene sequencing and mpsA gene sequencing.

Trial sites (1)

FacilityCityRegionStatus
Dermatology Department Bispebjerg Copenhagen Denmark Recruiting

More University Hospital Bispebjerg and Frederiksberg trials in Denmark

Lithium Versus Lamotrigine in Bipolar Disorder, Type II Recruiting
Pre- and Postoperative Chest Therapy With Positive Expiratory Pressure (PEP) to Prevent Hospital-acquired Pneumonia Recruiting
Weighted Blankets for Sleep Disturbance Among Children With ADHD Recruiting
Test of Reproducibility of [15O]H20-PET Assessment of Brain Perfusion Starting soon
Retail-Grade Weighted Blanket Effectiveness on ADHD-related Sleep Disturbances (BEAD) Recruiting

Other trials for the same condition

A Study to Assess the Impact of Lebrikizumab on Health-Related Well-Being and Control of Skin Manifestations in Participants With Moderate-to-Severe Atopic Dermatitis Recruiting
Methotrexat to Hand Eczema in the BIOSKIN Cohort Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07807228 on ClinicalTrials.gov ↗ ← All trials in Denmark